Introduction
Aspirin is a cornerstone of treatment in all forms of coronary artery disease (CAD). 1 In particular, dual antiplatelet therapy combining aspirin and a P2Y12 inhibitor is required in patients treated for acute coronary syndromes as well as for patients undergoing stent placement during percutaneous coronary intervention (PCI). However, patients with a history of aspirin hypersensitivity, which affects 0.5-2.4% of patients, 2, 3 are often denied this potentially life-saving therapy. Aspirin hypersensitivity appears directly related to an imbalance of eicosanoid metabolism towards the leucotriene pathway, which may lead to platelet activation via the release of reactive oxygen species involving the activation of lipoxygenase. 4 Patients with aspirin hypersensitivity can undergo successful desensitization and subsequently receive safely prolonged treatment with low doses of aspirin. [5] [6] [7] [8] [9] Little is known, however, about the antiplatelet efficacy of aspirin in these patients. Furthermore, although basophils and mastocytes are known to be involved in aspirin hypersensitivity, 10 ,11 the ability of basophils to be activated ex vivo by aspirin before and after desensitization has never been documented. New insights into this process might help to better understand the aspirin desensitization mechanism. We therefore designed a case-control study to test the antiplatelet efficacy of aspirin measured 1 day (D1) and at steady state 6-8 weeks (W6-8) after desensitization, and the reality of antiplatelet protection and also platelet activation. A secondary objective was to determine the efficacy of desensitization on ex vivo basophil reactivity to aspirin 6-8 weeks after desensitization.
Methods
Patients were admitted in the Department of Cardiology in either the Bichat or the Cochin Hospital, Paris, France. Cases had a history of aspirin hypersensitivity, based on anamnesis, with mandatory indications for aspirin, such as acute coronary syndromes, or placement of a stent, and underwent desensitization after admission, as described. Briefly, all patients received the same protocol with four sequential doses (5, 10, 20 , and 40 mg) of aspirin with the procedure lasting 2.5 h 7 and 75 mg the next morning. Controls were patients admitted for stable CAD and were being treated with 75-250 mg/day of aspirin without hypersensitivity to aspirin. Exclusion criteria were ongoing ST-segment elevation myocardial infarction (STEMI) (after stabilization and revascularization STEMI patient could be included), exacerbation of asthma, Quincke's oedema, and any other allergic manifestation in progress.
In cases, samples were collected at D0, D1, and at steady state between 6 weeks and 8 weeks after desensitization, whereas in controls only one sample was collected, considering the chronic treatment with aspirin and the stable condition of the patients. Detailed descriptions of measurement methods are available in the supplementary material online.
The study was approved by the institutional review board of Hotel Dieu (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale, Hôtel Dieu, Paris, IRB authorization number 0611301), Paris, France. All patients provided written informed consent. The trial was registered (Clinical Trials.gov identifier: NCT01118546).
The characteristics of patients are described using frequency and percentage for categorical variables, and mean 6 standard deviation or median with interquartile range for continuous variables. Among cases, results at D0, D1, and W6-8 were compared for inhibition of platelet aggregation, urinary thromboxane B 2 , platelet expression of P-selectin, 
Results
Between 2007 and 2013, we enrolled 56 cases with a history of aspirin sensitivity and 35 controls without a history of aspirin sensitivity; all were treated with aspirin. Clopidogrel (75 mg/day) was also used in 40 of 56 cases and in 12 of 35 controls at baseline. No patient was under other antiplatelets. The main clinical characteristics of cases and controls are described in Table 1 .
Of 56 cases, 27 (48%) presented with acute coronary syndrome (ACS), including five with STEMI (desensitized after stabilization), and 29 patients were treated for stable CAD. Patients with ACS were treated with usual doses of clopidogrel (300-600 mg loading dose followed by 75 mg daily) before undergoing desensitization. The mean age was 65.8 6 11.2 years, 71% were men, and over half had hypertension (55%) and hyperlipidemia (58%). Approximately onethird of the cases had diabetes (36%) and 26% had a family history of CAD. The previous hypersensitivity symptoms are described in Table 2 . History of hypersensitivity included severe symptoms in onequarter of the patients (13/44): bronchospasm or angio-oedema in nine cases, anaphylactic shock in three patients, and Widal syndrome (polyposis, asthma and aspirin hypersensitivity) in one patient. None had ongoing sensitivity manifestations. All patients underwent rapid and uneventful desensitization at a median (interquartile range) delay of 17 h (4.0-24.0 h) after admission. Angioplasty was performed in 24 patients, uneventfully, a median (interquartile range) of 24 h (20.0-24.0 h) after desensitization. Drug-eluting stents were implanted in 14 patients. No major adverse cardiac event occurred during the 6-8 weeks after the desensitization procedure; and all patients except one remained on aspirin. The only discontinuation was due to poor compliance. One patient required an elective PCI as planned during the index hospitalization. At 6-8 week follow-up, no hypersensitivity symptoms linked to aspirin sensitivity were reported.
Control subjects were all outpatients with stable CAD, treated with aspirin, representing an efficient baseline reference in terms of aggregability state. None had a recent, <1 year, history of ACS. Their mean age was 68.8 6 8.8 years. There were no statistically significant differences from cases in terms of age, sex, risk factors, or medical history, except for a less frequent family history of CAD, more frequent history of myocardial infarction, coronary artery bypass graft surgery, heart failure, and low left ventricular ejection fraction in controls (Table 1) (Figure 1a) . The only patient with persistent platelet aggregation at W6-8 had a poor compliance to aspirin. In controls, 100% of patients achieved a light transmission aggregometry induced by arachidonic acid 20% (P ¼ 0.39 vs. cases at W6-8).
In cases, median (interquartile range) urinary thromboxane B 2 decreased from 1605 (1200-1889) pg/mL to 1000 (0-1250) pg/mL between D0 and W6-8 (P < 0.0001) but remained higher when compared with controls [700 (550-882) pg/mL; P ¼ 0.03] (Figure 1b) .
The study of platelet activation by flow cytometry on whole blood, using platelet expression of P-selectin, activated glycoprotein IIb/IIIa, and platelet-monocyte aggregates, showed that platelet activation was similar at D0 and D1 but had dropped substantially at S6-8 (Figure 2a-c ). In controls, the level of platelet activation was higher than in cases after 6-8 weeks of treatment.
The quantification of basophil activation in response to aspirin ex vivo showed an increase of CD203c MFI index from 3.6 (interquartile range 1.4-5.4) at D0 to 8.1 (6.0-12.0) at W6-8 (P ¼ 0.0046) in cases (Figure 3a) without any significant modification of CD63 expression: 5% (interquartile range 4-8%) at D0 vs. 6% (interquartile range 3-10%) at W6-8 (P ¼ 0.32). Basophils from controls (CD203c MFI 
Discussion
This case-control study confirms the previous observation that patients with CAD and a history of aspirin hypersensitivity can be administered aspirin safely and can undergo rapid PCI.
2,3,5-8,12,13 Use of drug-eluting stents, as for the majority of the cases, appeared safe: there was no stent thrombosis during the 2 months follow-up of the desensitized patients. More importantly, it provides evidence that aspirin achieves effective and sustained inhibition of platelet aggregation in response to arachidonic acid. The efficacy of aspirin at D1 did not quite reach that achieved in chronically treated controls, but it appeared indistinguishable in cases and controls 6-8 weeks after desensitization. Measurements of urinary thromboxane B 2 were consistent and also showed a delayed efficacy of aspirin in inhibiting the generation of thromboxane, which, however, remained slightly higher than in controls 6-8 weeks after desensitization. Finally, the progressive onset of aspirin efficacy was associated with decreased platelet activation at follow-up. The lower level of platelet activation observed in cases may be related to the higher proportion who received dual antiplatelet therapy compared with controls (74% vs. 34%, respectively). Interestingly, even though there was no further clinical manifestation of aspirin hypersensitivity after desensitization, there was biological evidence of a persistent hyper-response to aspirin, as shown by an ex vivo hyper-response of basophils to aspirin and increased leucotriene levels. This could explain the reported mandatory need for a novel desensitization in case of aspirin withdrawal more than 5 days. 14, 15 This novel procedure could be performed safely respecting the same protocol. 7 An important limitation of the study was that controls were not matched. Cases comprised nearly half patients with an acute coronary syndrome, whereas controls were those treated for CAD, few of whom received dual antiplatelet therapy. Cases were treated with a daily dose of 75 mg of aspirin, majority of controls with doses varying from 75 to 160 mg, only four of them received 250 mg daily. This disparity could explain part of the difference observed in terms of platelet activation. However, regarding the differences in aspirin dosing, it has been reported that in state coronary disease, (and in the dose range explored in this study i.e. below 500mg) the biological response to aspirin is mostly related to time after aspirin intake rather than to the dosage by itself: thus no significant differences were found between lower (75-100 mg/day) and higher (> 100 mg/day) dose aspirin. 16 Likewise, combination of clopidogrel with aspirin has not been reported to modify on-aspirin platelet reactivity in response to arachidonic acid, which is highly specific of the cyclooxygenase pathway. 17 Second, despite the prospective study design, not all cases were tested at follow-up, leading to some missing data. Third, platelet aggregation was performed in the morning; however, the delay between the last intake of medication and performance of the test was not controlled and may have affected the results.
In conclusion, after rapid oral desensitization, platelet inhibition is achieved rapidly at D1, moreover, at steady state, complete inhibition is comparable to that of controls. Persistent basophil activation several weeks after desensitization suggests infraclinical hypersensitivity and the need therefore to continue aspirin treatment to maintain desensitization. Platelet and basophil activity after rapid aspirin desensitization
